drugset / Trial / NCT00134199

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199

Phase 2/3 Completed 282 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression

Timeline

Start
2005-03
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject OTENABANT Small molecule
Subject Sibutramine Small molecule

Indications